Burke T R, Nomizu M, Otaka A, Smyth M S, Roller P P, Case R D, Wolf G, Shoelson S E
Laboratory of Medicinal Chemistry, NCI, National Institutes of Health, Bethesda, MD 20892.
Biochem Biophys Res Commun. 1994 Jun 30;201(3):1148-53. doi: 10.1006/bbrc.1994.1825.
Cyclic hexameric peptides based on the amino acid sequence "Gly-Xxx-Val-Pro-Met-Leu", where Xxx is either phosphotyrosyl (pTyr) residue or a hydrolytically stable pTyr mimetic, were examined for their ability to bind to the C-terminal SH2 domain of the p85 phosphoinositol 3-kinase (PI 3-kinase). The cyclic peptides retained significant binding affinity relative to their linear counterparts. Potency varied depending on Xxx in the order: phosphonomethyl phenylalanine (Pmp, ID50 = 5.2 microM) < phosphonodifluoromethyl phenylalanine (F2Pmp, ID50 = 2.2 microM) < pTyr (ID50 = 1.0 microM), with Xxx = Tyr being inactive (ID50 > 500 M). Greatly reduced potency was observed when Xxx was of the unnatural D-configuration. The cyclic peptides represent conformationally constrained ligands which should be useful in the development of p85 SH2 domain-directed inhibitors.
对基于氨基酸序列“甘氨酸-Xxx-缬氨酸-脯氨酸-甲硫氨酸-亮氨酸”的环状六聚体肽进行了研究,其中Xxx为磷酸酪氨酸(pTyr)残基或水解稳定的pTyr模拟物,考察它们与p85磷酸肌醇3激酶(PI 3激酶)C末端SH2结构域结合的能力。相对于线性对应物,环状肽保留了显著的结合亲和力。效力根据Xxx的不同而变化,顺序为:膦酰甲基苯丙氨酸(Pmp,半数抑制浓度ID50 = 5.2微摩尔)<二氟膦酰甲基苯丙氨酸(F2Pmp,ID50 = 2.2微摩尔)<pTyr(ID50 = 1.0微摩尔),而当Xxx为酪氨酸时无活性(ID50>500微摩尔)。当Xxx为非天然D构型时,效力大大降低。环状肽代表构象受限的配体,在开发p85 SH2结构域导向抑制剂方面应会有用。